Biblio
Journal Article
Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2020.
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, de Graauw NC van der, Schouten HC, Bilgin YM, et al. Rituximab-PECC induction followed by Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019.